Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 6Unknown 3Terminated 2Recruiting 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 8INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1

Conditions

Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Immunotherapy × Clear all
NCT02054520 2023-04-18

Immunotherapy Study for Patients With Stage IV Melanoma

Lumos Pharma

Phase 2 Terminated
47 enrolled 16 charts
Dermatologic

Melanoma

NCT00089856 2008-11-05

GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

Cell Genesys

Phase 3 Terminated
626 enrolled
Genitourinary

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡